LONDON, Nov 14 (Reuters) - Novo Nordisk ... injecting insulin. Some diabetes patients in the U.S. have this year pushed back against the company's decision to stop selling its long-acting insulin ...

Novo Nordisk is gradually ending production of human insulin pens, the drugmaker told Reuters, as it spends billions to ramp ...

For many patients with type 2 diabetes, having to inject basal insulin every day is a burdensome fact of life, but Novo Nordisk is trying ... up at mealtimes with fast-acting insulins.

Levemir (insulin detemir) has a shorter duration of action than other long-acting basal insulins like Sanofi's Lantus (insulin glargine) and biosimilars and Novo Nordisk's newer product Tresiba ...

The leading healthcare company specializing in diabetes care was honored with awards under the Inspirational Brand, Fast Enterprise ... Founded in Denmark in 1923, Novo Nordisk has a rich history. The ...

began with the insulin analogue desB30 (used to produce the long-acting insulin degludec ... by lowering the risk of hypoglycaemia. Novo Nordisk is currently conducting further research and ...

Halozyme makes 2 billion euro buyout offer for drug developer Evotec November 14, 2024 Novo Nordisk is gradually ending production of human insulin pens ... the race in the fast-growing obesity ...

Novo Nordisk is ceasing production of human insulin pens, focusing on newer obesity and diabetes injections. This shift has ...

Novo Nordisk (NVO) reportedly plans to phase out production of human insulin pens while it ramps up production of other ...

As sales of Novo Nordisk’s GLP-1 drugs for diabetes and obesity continue to soar, the Danish drugmaker is once again ...

About 400 people marched to the South African headquarters of Novo Nordisk A/S in Johannesburg this week demanding greater ...